It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

The firm has done a great job in bringing this balance down over the last three years but we do see some potential risk in the near term. Roughly 40% of debt is set to expire over the next three years ...

CVS sees 23% revenue growth in healthcare benefits & projects 10% EPS in 2025, with Aetna recovery boosting performance.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Feb. 25, 112 pharmacies across Alabama closed to express support for Senate Bill 93 in the Alabama legislature. While no ...

The three largest pharmacy benefit managers are looking to take their legal back-and-forth with the Federal Trade Commission ...

Pharmacy Benefit Managers (PBMs) have evolved from relatively obscure cost-saving entities into powerful industry players ...

The “Big Three” PBMs are kicking their suit up to the 8th Circuit and, in the meantime, are once again asking a Missouri ...

CVS director Mike Mahoney, whose day job is CEO of Boston Scientific, bought 30,000 shares of the healthcare company.

CHARLOTTE — Two counties in the Charlotte area have filed lawsuits in the last few weeks over the price of insulin. Gaston County and Lincoln County join hundreds of similar lawsuits against drug ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against other ...